FindTrial
Sign In

CAMPATH-1H AS IMMUNOSUPPRESSIVE AGENT IN MDS PATIENTS MULTICENTRIC PILOT STUDY

CAMPATH-1H AS IMMUNOSUPPRESSIVE AGENT IN MDS PATIENTS MULTICENTRIC PILOT STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001774-27-IT
Enrollment
Unknown
Registered
2005-06-21
Start date
2005-05-23
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In this study we want to assess the potential of CAMPATH-1H as an immunosuppressive agent in a series of selected MDS patients, because T lymphocytes are thought to play an important role in the pathogenesis of cytopenia in MDS. MedDRA version: 6.1 Level: HLT Classification code 10028536

Interventions

Trade Name: mabcampath 1h Product Name: NA Product Code: NA Pharmaceutical Form: Emulsion for infusion INN or Proposed INN: Alemtuzumab Concentration unit: mg milligram(s) Concentration type: equal Co

Sponsors

AISSM ONLUS
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026